5N9B | pdb_00005n9b

Crystal Structure of unliganded human IL-17RA

• PDB DOI: https://doi.org/10.2210/pdb5N9B/pdb

• Classification: SIGNALING PROTEIN
• Organism(s): Homo sapiens
• Expression System: Homo sapiens
• Mutation(s): No 


• Deposited: 2017-02-24 Released: 2018-06-13 
• Deposition Author(s): Rondeau, J.-M., Goepfert, A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 
  0.234 (Depositor), 0.243 (DCC) 
• R-Value Work: 
  0.190 (Depositor), 0.198 (DCC) 
• R-Value Observed: 
  0.192 (Depositor) 

Starting Model: experimental

Literature

IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling.

Goepfert, A., Barske, C., Lehmann, S., Wirth, E., Willemsen, J., Gudjonsson, J.E., Ward, N.L., Sarkar, M.K., Hemmig, R., Kolbinger, F., Rondeau, J.M.

(2022) Cell Rep 41: 111489-111489

• PubMed: 36260993 
• DOI: https://doi.org/10.1016/j.celrep.2022.111489
• Primary Citation Related Structures: 
  5N9B, 7ZAN


• PubMed Abstract: 
  

  Signaling through innate immune receptors such as the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily proceeds via the assembly of large membrane-proximal complexes or "signalosomes." Although structurally distinct, the IL-17 receptor family triggers cellular responses that are typical of innate immune receptors. The IL-17RA receptor subunit is shared by several members of the IL-17 family. Using a combination of crystallographic, biophysical, and mutational studies, we show that IL-17A, IL-17F, and IL-17A/F induce IL-17RA dimerization. X-ray analysis of the heteromeric IL-17A complex with the extracellular domains of the IL-17RA and IL-17RC receptors reveals that cytokine-induced IL-17RA dimerization leads to the formation of a 2:2:2 hexameric signaling assembly. Furthermore, we demonstrate that the formation of the IL-17 signalosome potentiates IL-17-induced IL-36γ and CXCL1 mRNA expression in human keratinocytes, compared with a dimerization-defective IL-17RA variant.

---

Organizational Affiliation: 
• Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA.
Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. Electronic address: [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: gel filtration

Macromolecule Content 

• Total Structure Weight: 34.08 kDa 
• Atom Count: 2,234 
• Modeled Residue Count: 244 
• Deposited Residue Count: 286 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Interleukin-17 receptor A	A	286	Homo sapiens	Mutation(s): 0  Gene Names: IL17RA, IL17R
UniProt & NIH Common Fund Data Resources
Find proteins for Q96F46 (Homo sapiens) Explore Q96F46  Go to UniProtKB:  Q96F46
PHAROS:  Q96F46 GTEx:  ENSG00000177663
Glycosylation
Glycosylation Sites: 4		Go to GlyGen: Q96F46-1

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
NAG	B [auth A], C [auth A], D [auth A], E [auth A]	2-acetamido-2-deoxy-beta-D-glucopyranose C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free:  0.234 (Depositor), 0.243 (DCC) 
• R-Value Work:  0.190 (Depositor), 0.198 (DCC) 
• R-Value Observed: 0.192 (Depositor) 

Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 40.593	α = 90
b = 71.685	β = 90
c = 105.385	γ = 90

Software Package:

Software Name	Purpose
XSCALE	data scaling
BUSTER	refinement
PDB_EXTRACT	data extraction
XDS	data reduction
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2018-06-13 
Deposition Author(s): Rondeau, J.-M., Goepfert, A.

Revision History  

• Version 1.0: 2018-06-13
  Type: Initial release
  
• Version 1.1: 2019-06-12
  Changes: Data collection, Database references
• Version 1.2: 2020-07-29
  Type: Remediation
  Reason: Carbohydrate remediation
  Changes: Data collection, Derived calculations, Structure summary
• Version 1.3: 2022-11-02
  Changes: Database references, Structure summary
• Version 1.4: 2024-01-31
  Changes: Data collection, Refinement description
• Version 1.5: 2024-11-06
  Changes: Structure summary